Showing results 1 to 5 of 5
Title | Author(s) | Issue Date | |
---|---|---|---|
Activity of brigatinib (BRG) in crizotinib (CRZ) resistant patients (pts) according to ALK mutation status Proceeding/Conference:Journal of Clinical Oncology | 2016 | ||
Alectinib (ALC) vs crizotinib (CRZ) in treatment-naïve ALK+ non-small-cell lung cancer (NSCLC): Asian vs non-Asian subgroup analysis of the ALEX study Proceeding/Conference:European Society for Medical Oncology (ESMO) Asia Congress, 2017 | 2017 | ||
Chronic myeloid leukemia in Asia Journal:International Journal of Hematology | 2009 | ||
First-line lorlatinib versus crizotinib in ALK-positive non-small cell lung cancer: Asian subgroup analysis of CROWN Proceeding/Conference:Annals of Oncology | 2021 | ||
2008 |